Moore Wesley S
Division of Vascular and Endovascular Surgery, UCLA Medical Center, Los Angeles, CA, USA
Angiology. 2016 May;67(5):408-10. doi: 10.1177/0003319715611281. Epub 2015 Oct 11.
The superiority of carotid endarterectomy (CEA) plus best medical treatment (BMT) over BMT alone for the management of patients with asymptomatic carotid stenosis is based on randomized controlled trials that recruited patients up to 30 years ago. Best medical treatment has improved considerably since that time with respect to stroke prevention. Furthermore, a new carotid intervention has emerged during the last 2 decades and has gradually become established, that is, carotid artery stenting (CAS). Consequently, the efficacy of current BMT alone needs to be compared not only with CEA plus BMT but also with CAS plus BMT to determine which strategy achieves the optimal stroke prevention rates. This article highlights the purpose of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) 2 and discusses the issues that CREST-2 will hopefully provide answers to.
对于无症状性颈动脉狭窄患者的治疗,颈动脉内膜切除术(CEA)联合最佳药物治疗(BMT)优于单纯BMT,这一结论基于30年前招募患者的随机对照试验。自那时以来,在预防中风方面,最佳药物治疗有了显著改善。此外,在过去20年中出现了一种新的颈动脉干预措施,并逐渐得到确立,即颈动脉支架置入术(CAS)。因此,不仅需要将当前单纯BMT的疗效与CEA联合BMT的疗效进行比较,还需要与CAS联合BMT的疗效进行比较,以确定哪种策略能实现最佳的中风预防率。本文重点介绍了颈动脉血运重建内膜切除术与支架置入术试验(CREST)2的目的,并讨论了CREST-2有望给出答案的问题。